Compare Marathon Petroleum Corp (MPC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs 10X Genomics Inc — how do they compare? Marathon Petroleum Corp trades at $455.46 (market cap $130.12B), while 10X Genomics Inc trades at $80.87 (market cap $10.07B). The key difference: Marathon Petroleum Corp is far larger — about 12.9× 10X Genomics Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and 10X Genomics Inc for 91 Days on average.
| MPC | TXG | |
|---|---|---|
Market Cap | $130.12B | $10.07B |
Volume | 2,749,647 | 5,657,286 |
Sector | Energy | Health |
52-Week High | $463.34 | $97.74 |
52-Week Low | $162.63 | $11.48 |
Typical Hold Time | 54 Days | 91 Days |
Enterprise Value | $156.64B | $9.59B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $455.03, up 2.89% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 16.07, ROE of 47.9%, and consistent earnings beats in recent quarters. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions pose headwinds.
Outlook remains positive with 76% analyst buy ratings and $420.30 consensus target. Key opportunities include elevated refining margins and projected 2026 revenue growth to $153.6B. Risks include regulatory uncertainty around diesel exports and declining operating cash flow from 2022 peaks.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
